News & Updates
Filter by Specialty:
GLP-1 RA plus SGLT-2i better than monotherapy for CV, renal events prevention
Patients with type 2 diabetes (T2D) who received combined treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RA) and sodium-glucose cotransporter-2 inhibitors (SGLT-2i) have a much lower risk of major adverse cardiovascular events (MACE) and serious renal events than those treated with either drug class alone, suggests a recent study.
GLP-1 RA plus SGLT-2i better than monotherapy for CV, renal events prevention
04 May 2024
Semaglutide benefits extend to HFpEF patients with T2D
The weight loss and heart failure (HF) benefits of semaglutide extend to patients with obesity-related HF with preserved ejection fraction (HFpEF) and type 2 diabetes (T2D) in the STEP-HFpEF DM trial, fuelling speculation that semaglutide may have cardiovascular effects beyond weight loss.
Semaglutide benefits extend to HFpEF patients with T2D
04 May 2024
Prognosis role of blood urea nitrogen to serum albumin ratio established in IPAH
A higher ratio of blood urea nitrogen to serum albumin is indicative of worse outcomes and disease severity in patients with idiopathic pulmonary arterial hypertension (IPAH), according to a study.
